On October 11th, according to The Paper, the National Medical Products Administration approved shanghai junshi bio Pharmaceutical Technology Co., Ltd.'s application for the listing of Angkorixi Monoclonal Antibody Injection (brand name: Junshida). This is the 5th domestically produced first-class innovative drug approved for listing in Shanghai this year. The Shanghai Food and Drug Administration revealed that in 2024, Shanghai has a total of 5 domestically produced first-class innovative drugs, 3 imported innovative drugs, and 9 Class III innovative medical instruments approved for listing. As of now, the number of approved innovative drugs in Shanghai has exceeded last year, while the number of approved innovative medical instruments is the same as last year. The Shanghai Food and Drug Administration is actively implementing the "one list, two optimizations, three linkages" service innovation mechanism, implementing "one product, one company, one strategy" for key products and projects, supporting the research and development and listing of innovative products; strengthening post-market supervision of products to ensure the safety of medication and medical instruments for patients.
上海今年第五款国产1类创新药获批上市 获批创新药已超去年
This year, the fifth domestic Class 1 innovative drug in shanghai has been approved for market launch. The approved innovative drugs have exceeded last year.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated